Vaxcyte surges 25.6% in pre-market; pneumococcal vaccine meets late-stage trial target

智通财经2026/10/05 10:32

Show original

Vaxcyte's stock price surged 25.6% in pre-market trading in the US, after the company's pneumococcal vaccine achieved its late-stage clinical trial goals.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Elon Musk said his company may find a better way to manufacture chips.

智通财经•2026/10/11 07:36

BP is safely restarting production at its Na Kika and Thunder Horse platforms in the Gulf of Mexico.

智通财经•2026/10/11 05:16

BP is safely restarting production at the Na Kika and Thunder Horse platforms.

智通财经•2026/10/11 04:46

The overseas asset returns of the Bank of Korea are expected to reach nearly 17 trillion won in 2025, a year-on-year increase of 32%.

智通财经•2026/10/11 04:06